9999999997-18-005607.txt : 20180508 9999999997-18-005607.hdr.sgml : 20180508 20180508114443 ACCESSION NUMBER: 9999999997-18-005607 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180508 DATE AS OF CHANGE: 20180508 ACTION DATE: 20180508 RECEIVED DATE: 20180508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Dare Bioscience, Inc. CENTRAL INDEX KEY: 0001401914 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 204139823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-36395 FILM NUMBER: 18813505 BUSINESS ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-769-9145 MAIL ADDRESS: STREET 1: 11119 NORTH TORREY PINES ROAD STREET 2: SUITE 200 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: Cerulean Pharma Inc. DATE OF NAME CHANGE: 20090714 FORMER COMPANY: FORMER CONFORMED NAME: Tempo Pharmaceuticals Inc DATE OF NAME CHANGE: 20070604 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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